Table 3 Diagnostic test statistics of the study cohort showing the accuracy and missed cancer rates for each phi threshold as a triage test pre-MRI and biopsy. PSAd thresholds are shown as a comparator though this metric is not usually available before an mpMRI. Detection rates for cancer are shown using definitions of ≥ Grade Group 2 (GG2) or ≥ Cambridge Prognostic Group 3 [CPG3]. (*percentage out of 258 cancers detected, ** percentage out of 176 cancers detected)

From: Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study